# US 2025/0375471 A1 · Heparanase inhibitors and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375471 A1
- Document ID: US20250375471A1
- Status: Published application
- Kind: A1
- Application number: 18/876,815
- Filed: 2023-06-23
- Published: 2025-12-11
- Earliest claimed: 2022-06-24
- Assignees: The Board of Regents of the University of Oklahoma
- Applicants: The Board of Regents of the University of Oklahoma
- Inventors: Paul L. DEANGELIS; Dixy E. GREEN
- Web page: https://patentgrep.com/patent/US20250375471A1

## CPC

- A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C08B 37/0063: {Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan}
- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C08L 5/10: Heparin; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Polymers comprising the repeat structure [4-D-glucuronic acid-α1,4-D-N-acetylglucosamine-α1-]n ([-4-D-GlcUA-α1,4-D-GlcNAc-α1-]n) are disclosed, wherein at least one sulfur moiety is linked to at least one hydroxyl of the repeat structure. Also disclosed are methods of producing and using these polymers.

## Claims

### Claim 1

A polymer, comprising the repeat structure [4-D-glucuronic acid-α1,4-D-N-acetylglucosamine-α1-]n ([-4-D-GlcUA-α1,4-D-GlcNAc-α1-]n), wherein at least one sulfur moiety is linked to at least one hydroxyl of the repeat structure, and wherein n is in a range of from about 2 to about 500.

### Claim 2 (depends on 1)

The polymer of claim 1, wherein the sulfur moiety is SO3.

### Claim 3 (depends on 1)

The polymer of claim 1, comprising the structure O-Sulfo [-4-GlcUA-α1,4-GlcNAc-α1-]n.

### Claim 4 (depends on 1)

The polymer of claim 1, wherein the sulfur moiety is O-linked to the GlcNAc.

### Claim 5 (depends on 1)

The polymer of claim 1, wherein the sulfur moiety is O-linked to the GlcUA.

### Claim 6 (depends on 1)

A composition, comprising the polymer of claim 1.

### Claim 7 (depends on 6)

The composition of claim 6, wherein the composition is in an aqueous solution.

### Claim 8 (depends on 1)

A composition, comprising:
at least one polymer of claim 1; and
a heparosan chain or other polymer linked thereto.

### Claim 9 (depends on 1)

A method of inhibiting heparanase activity, comprising exposing the heparanase to at least one polymer of claim 1.

### Claim 10 (depends on 6)

A method of inhibiting heparanase activity, comprising exposing the heparanase to at least one composition of claim 6.

### Claim 11 (depends on 9)

The method of claim 9, wherein the heparanase activity is inhibited in vitro.

### Claim 12 (depends on 9)

The method of claim 9, wherein the heparanase activity is inhibited in vivo.

### Claim 13 (depends on 1)

A pharmaceutical composition, comprising:
at least one polymer of claim 1; and
a pharmaceutically acceptable excipient.

### Claim 14 (depends on 13)

A method of treating a subject in need of treatment, comprising the step of:
administering the pharmaceutical composition of claim 13 to the subject in need of treatment.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject has cancer or is predisposed to cancer.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject has at least one disease or condition associated with overexpression, misregulation, or hyperactivity of heparanase.

### Claim 17 (depends on 16)

The method of claim 16, wherein the at least one disease or condition is selected from the group consisting of diabetes, a complication of diabetes, atherosclerosis, thrombosis, a viral infection, and combinations thereof.

### Claim 18

A method of producing a sulfated testan polymer, the method comprising the steps of:
producing a polymer backbone having the repeat structure [4-D-glucuronic acid-α1,4-D-N-acetylglucosamine-α1-]n ([-4-D-GlcUA-α1,4-D-GlcNAc-α1-]n), wherein n is in a range of from about 2 to about 500; and
linking at least one sulfur moiety to at least one hydroxyl of the repeat structure.

### Claim 19 (depends on 18)

The method of claim 18, wherein the polymer backbone is produced by native fermentation or recombinant production using an organism expressing a testosteronan synthase gene.

### Claim 20 (depends on 18)

The method of claim 18, wherein the polymer backbone is produced by chemical or chemoenzymatic synthesis.

### Claim 21 (depends on 1)

A kit, comprising at least one polymer of claim 1.

### Claim at position 22

22-23. (canceled)
